Simon Dumesnil Biography and Net Worth



Simon Dumesnil has served on our board of directors since April 2021. He is currently a Managing Partner and Director of Dunraven Capital Partners Limited, an investment management advisory company incorporated in the UK whose investments are predominately in Eastern European corporate distressed credits and structured products. From 2013 to 2018, Mr. Dumesnil was Managing Director and Head of Structured Financing Group Americas of UBS Securities LLC, where he was responsible for the structured financing trading book in the USA and LATAM and managed a book of financing positions across fixed income products (corporate syndicated and middle-market loans, corporate bonds, real estate loans, CMBS/RMBS/CLO/ABS, LATAM Sovereign). From 2010 to 2013, he was Managing Director and Co-Head Private-Side Structuring Group EMEA of UBS AG., where he was responsible for arranging structured solution transactions and acquisitions for FIG and Special Situation Group (SSG) and also co-headed the illiquid financing business. From 2009 to 2010, Mr. Dumesnil was the Chief Investment Officer Bluestone Capital Management and responsible for investments in distressed assets across Europe. From 2008 to 2009, Mr. Dumesnil was Director of Lehman Brother Holding Inc. and responsible for restructuring and unwinding Lehman Brothers Special Financing Inc. derivative book post-bankruptcy. From 2003 to 2008, Mr. Dumesnil was Director of Lehman Brothers International (Europe). Throughout his career at Dunraven Capital Management, UBS Securities, UBS AG, Bluestone Capital Management and Lehman Brothers, Mr. Dumesnil advised and underwritten corporate risk related to companies across industries or jurisdictions. He has an in-depth knowledge on corporate restructuring and capital structure optimization for companies across their business life cycle. His experience as Chief Investment Officer during the launch and growth phases of a financial services and technology company represents valuable insights for our Company. Mr. Dumesnil attended Cass Business School, where he received his Master of Science in Banking and International Finance and École des Hautes-Études-Commerciales HEC, where he received his Bachelor in Business and Administration, Finance.

What is Simon Dumesnil's net worth?

The estimated net worth of Simon Dumesnil is at least $17.74 thousand as of November 28th, 2025. Mr. Dumesnil owns 35,833 shares of Pasithea Therapeutics stock worth more than $17,737 as of October 2nd. This net worth evaluation does not reflect any other investments that Mr. Dumesnil may own. Learn More about Simon Dumesnil's net worth.

How do I contact Simon Dumesnil?

The corporate mailing address for Mr. Dumesnil and other Pasithea Therapeutics executives is 1111 Lincoln Road Suite 500, Miami Beach FL, 33139. Pasithea Therapeutics can also be reached via phone at 702-514-4174 and via email at [email protected]. Learn More on Simon Dumesnil's contact information.

Has Simon Dumesnil been buying or selling shares of Pasithea Therapeutics?

Simon Dumesnil has not been actively trading shares of Pasithea Therapeutics during the past quarter. Most recently, on Friday, November 28th, Simon Dumesnil bought 33,333 shares of Pasithea Therapeutics stock. The stock was acquired at an average cost of $0.75 per share, with a total value of $24,999.75. Following the completion of the transaction, the director now directly owns 35,833 shares of the company's stock, valued at $26,874.75. Learn More on Simon Dumesnil's trading history.

Who are Pasithea Therapeutics' active insiders?

Pasithea Therapeutics' insider roster includes Simon Dumesnil (Director), and Lawrence Steinman (Director). Learn More on Pasithea Therapeutics' active insiders.

Are insiders buying or selling shares of Pasithea Therapeutics?

In the last twelve months, Pasithea Therapeutics insiders bought shares 3 times. They purchased a total of 199,999 shares worth more than $149,999.25. The most recent insider tranaction occured on November, 28th when CEO Tiago Marques bought 33,333 shares worth more than $24,999.75. Insiders at Pasithea Therapeutics own 1.5% of the company. Learn More about insider trades at Pasithea Therapeutics.

Information on this page was last updated on 11/28/2025.

Simon Dumesnil Insider Trading History at Pasithea Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/28/2025Buy33,333$0.75$24,999.7535,833View SEC Filing Icon  
See Full Table

Simon Dumesnil Buying and Selling Activity at Pasithea Therapeutics

This chart shows Simon Dumesnil's buying and selling at Pasithea Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pasithea Therapeutics Company Overview

Pasithea Therapeutics logo
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Read More

Today's Range

Now: $0.48
Low: $0.47
High: $0.51

50 Day Range

MA: $0.51
Low: $0.44
High: $0.60

2 Week Range

Now: $0.48
Low: $0.28
High: $2.06

Volume

48,874 shs

Average Volume

459,445 shs

Market Capitalization

$16.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34